Treatment Approach for Invasive Distal Carcinoma

Initial Evaluation

A thorough clinical, mammographic, and pathologic evaluation is essential to determine the extent and character of the disease before deciding on treatment options, as recommended by the American Cancer Society 1, 3
Physical examination should assess tumor size and location, nipple discharge or appearance, breast size to tumor ratio, axillary node status, and appearance of the opposite breast, according to the American Cancer Society 2, 4
Recent bilateral mammography (usually within 3 months) is required to establish the appropriateness of breast-conservation treatment by defining the extent of disease, as stated by the American Cancer Society 1, 5

Breast-conserving surgery with radiation therapy is appropriate for many patients with invasive distal carcinoma, as recommended by the American Cancer Society 1, 2
Key considerations for breast conservation include the extent of disease and patient's overall health status and ability to undergo radiation therapy, according to the American Cancer Society 1, 5 and the National Comprehensive Cancer Network 6

Mastectomy may be necessary in cases of extensive disease that cannot be completely excised with acceptable cosmetic results, as stated by the American Cancer Society 1, 3
Mastectomy may also be necessary in cases of multicentric disease, according to the American Cancer Society 5, 7

Proper orientation of the specimen is critical to ensure negative margins while avoiding excess tissue removal, as recommended by the American Cancer Society 8, 5
Specimen radiography should be performed intraoperatively to confirm removal of mammographic abnormalities, according to the American Cancer Society 8, 5

Sentinel lymph node biopsy (SLNB) is the standard approach for axillary staging in invasive carcinoma, as recommended by the National Comprehensive Cancer Network 6
For patients requiring mastectomy, a low axillary sampling or level I dissection may be performed to avoid a second procedure if invasive carcinoma is found, according to the American Cancer Society 8, 5

Systemic therapy decisions should be based on tumor characteristics, including hormone receptor status, HER2 status, and tumor grade, as recommended by the National Comprehensive Cancer Network 6

Post-treatment surveillance should include regular clinical examinations and mammography, as recommended by the American Cancer Society 5, 7

Inadequate preoperative imaging leading to incomplete tumor excision, as warned by the American Cancer Society 1, 5
Failure to properly orient specimens, making margin assessment difficult, according to the American Cancer Society 8, 5
Not considering patient factors (age, comorbidities, preferences) in treatment decision-making, as emphasized by the National Comprehensive Cancer Network 6 and the American Cancer Society 5